PMID: 6112412May 9, 1981Paper

A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates

Lancet
M S BergdollJ P Davis

Abstract

612 (93.8%) of 65 Staphylococcus aureus strains isolated from 65 patients with toxic-shock syndrome (TSS) produced an enterotoxin-like protein, tentatively identified as staphylococcal enterotoxin F (SEF). One of the other strains produced staphylococcal enterotoxin B and another exterotoxin C. In two blind studies all 34 TSS-associated S. aureau strains examined and 3 (11.5%) of 26 control S. aureau strains produced SEF. 2 of the latter strains were isolated from the vaginas of women who had no history of TSS. SEF was purified, and specific antibodies to it were prepared. Only 4 (4.6%) of 87 S. aureau strains from other sources were found to produce SEF. 5 (17.2%) of 29 TSS patients whose acute sera were available had anti-SEF antibody present in titres of greater than or equal to 1:100 as determined by radioimmunoassay, compared with 44 (78.6%) of 56 controls--demonstrating a greater serosusceptibility of TSS patients to SEF. It is suggested that staphylococcal enterotoxin, particularly SEF, may be a cause of the signs and symptoms of TSS.

Citations

Jan 1, 1994·Aesthetic Plastic Surgery·C A RheeI T Jackson
Aug 1, 1983·European Journal of Clinical Microbiology·G MauffG Pulverer
Jun 1, 1991·Diseases of the Colon and Rectum·E ShlaskoR M Steinhagen
Jan 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N LehnM Krönke
Jun 1, 1993·The International Journal of Biochemistry·F LicastroM C Morini
Apr 22, 1988·Journal of Immunological Methods·T A KuffnerB D Plikaytis
Jul 1, 1996·Molecular Immunology·R MakidaD Y Leung
Jan 1, 1982·Pharmacology & Therapeutics·J H Freer, J P Arbuthnott
Oct 1, 1995·International Journal of Immunopharmacology·K ImanishiT Uchiyama
Dec 1, 1994·Burns : Journal of the International Society for Burn Injuries·E A BachaR G Tompkins
Jul 1, 1988·FEMS Microbiology Immunology·J C de AzavedoJ P Arbuthnott
Nov 1, 1987·Veterinary Microbiology·B M BuddleH D Pulford
Mar 17, 2004·Burns : Journal of the International Society for Burn Injuries·Fujioka MasakiYamamoto Tsuneyuki
Mar 9, 2004·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Hirotsugu KanoJun Abe
Mar 11, 2004·Experimental and Molecular Pathology·Monesha Gupta-MalhotraJohn B Zabriskie
Feb 22, 1986·Lancet·J DevenishJ Goold
Jan 1, 1989·Zentralblatt Für Bakteriologie, Mikrobiologie, Und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology·A S NaiduT Wadström
Nov 24, 1999·Burns : Journal of the International Society for Burn Injuries·S J WitheyC C Walker
Nov 1, 1987·The Journal of Hand Surgery·M J Grayson, M J Saldana
Mar 23, 2000·Veterinary Microbiology·Y HayakawaS Takeuchi
Aug 8, 1998·The Journal of Emergency Medicine·D DavisE J Heffernan
Apr 18, 2000·Critical Care Clinics·D Simon, G Trenholme
Apr 18, 2000·FEMS Immunology and Medical Microbiology·T KobayashiM Kodama
Oct 1, 1995·Zentralblatt Für Bakteriologie : International Journal of Medical Microbiology·F Schumacher-PerdreauG Pulverer
Dec 1, 1985·The Journal of Hygiene·H J BeckersP D Tips
Feb 1, 1985·The Journal of Hygiene·A K MelconianY Brun
Jun 1, 1993·Epidemiology and Infection·A A WienekeR J Gilbert
Nov 18, 2008·Biochemistry·Amanda J BrosnahanPatrick M Schlievert
Sep 10, 1981·The New England Journal of Medicine·J R LentinoJ P Davis
Jun 10, 1982·The New England Journal of Medicine·W B CobbP L Moseley

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.